EU Reviews Johnson & Johnson Over Blood Clots, Widens AstraZeneca Probe

Four cases, one fatal, of rare clots with low blood platelets were reported among those vaccinated with the Johnson & Johnson shot, the European Medicines Agency (EMA) said in a statement.

The EU's drug regulator said Friday it is reviewing possible blood clot cases in people given the Johnson & Johnson coronavirus shot and probing a new condition linked to the AstraZeneca vaccine. Four cases, one fatal, of rare clots with low blood platelets were reported among those vaccinated with the Johnson & Johnson shot, the European Medicines Agency (EMA) said in a statement. Five cases meanwhile were reported of people suffering a rare condition in which tiny blood vessels leak after getting the AstraZeneca jab, causing swelling and a drop in blood pressure. "It is not yet clear whether there is a causal association" between the two vaccines and the cases, the Amsterdam-based EMA said in a statement.